✦ LIBER ✦

Low Incidence of Osteonecrosis of the Jaw in Postmenopausal Women With Osteoporosis Taking Zoledronic Acid Once Yearly

✍ Scribed by Cesar A. Migliorati

Book ID: 116634592
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 72 KB
Volume: 9
Category: Article
ISSN: 1532-3382
DOI: 10.1016/j.jebdp.2008.12.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of once-yearly infusion of zoledr

Effect of once-yearly infusion of zoledronic acid 5mg in postmenopausal women with osteoporosis

✍ Black, Dennis; Lewiecki, E. Micahel; Delmas, Pierre; Eastell, Richard; Reid, Ian 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Effects of once-yearly zoledronic acid 5

Effects of once-yearly zoledronic acid 5 mg in combination with teriparatide (PTH) on postmenopausal women with osteoporosis

✍ F. Cosman⁎; E.F. Eriksen; C. Recknor; P. Miller; S.L. Greenspan; P. Papanastasio 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 168 KB

Poster 150: Effect of Once-Yearly Infusi

Poster 150: Effect of Once-Yearly Infusion of 5mg of Zoledronic Acid in Postmenopausal Women With Osteoporosis: The HORIZON-Pivotal Fracture Trial

✍ Meryl S. LeBoff; Dennis Black; Pierre Delmas; Richard Eastell; Ian Reid; Steve C 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Pentoxifylline and Tocopherol in the Tre

Pentoxifylline and Tocopherol in the Treatment of Yearly Zoledronic Acid–Related Osteonecrosis of the Jaw in a Corticosteroid-Induced Osteoporosis

✍ Magremanne, Michèle; Reychler, Hervé 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 576 KB

Bone material properties in actively bon

Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid

✍ Sonja Gamsjaeger; Birgit Buchinger; Elizabeth Zwettler; Robert Recker; Dennis Bl 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 473 KB

Zoledronic acid (ZOL), a third-generation aminobisphosphonate, showed pronounced antifracture efficacy in a phase III clinical trial [Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT)] when administered yearly (5-mg infusions of ZOL), produci

The effects of intravenous zoledronic ac

The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis

✍ Jawl-Shan Hwang; Lin-Show Chin; Jung-Fu Chen; Tzay-Shing Yang; Po-Quang Chen; Ke 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 228 KB